MotesanibisaninhibitorofVEGFR1/2/3,PDGFR,c-Kit,andRETthatdisplaysanticancerchemotherapeuticandanti-angiogenicactivities.Invivo,motesanibinhibitstumorgrowthofxenograftsofvariouscancers.Motesanibiscurrentlyinclinicaltrialsasapotentialtreatmentfornon-smallcelllungcancer(NSCLC),breastcancer,andmedullarythyroidcancer.
| CasNo. | 857876-30-3 |
|---|---|
| Purity | ≥98% |
| Formula | C22H23N5O•2H3PO4 |
| FormulaWt. | 569.44 |
| IUPACName | N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]nicotinamidephosphate(1:2) |
| Appearance | Paleyellowpowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | M5877InfoSheetPDF |
|---|
EllisPM,Al-SalehK.Multitargetedanti-angiogenicagentsandNSCLC:clinicalupdateandfuturedirections.CritRevOncolHematol.2012Oct;84(1):47-58.PMID:22405734.
CoxonA,ZieglerB,KaufmanS,etal.Antitumoractivityofmotesanibaloneandincombinationwithcisplatinordocetaxelinmultiplehumannon-small-celllungcancerxenograftmodels.MolCancer.2012Sep19;11:70.PMID:22992329.
CoxonA,BreadyJ,KaufmanS,etal.Anti-tumoractivityofmotesanibinamedullarythyroidcancermodel.JEndocrinolInvest.2012Feb;35(2):181-90.PMID:21422803.
RaghavKP,BlumenscheinGR.MotesanibandadvancedNSCLC:experiencesandexpectations.ExpertOpinInvestigDrugs.2011Jun;20(6):859-69.PMID:21534718.
PolverinoA,CoxonA,StarnesC,etal.AMG706,anoral,multikinaseinhibitorthatselectivelytargetsvascularendothelialgrowthfactor,platelet-derivedgrowthfactor,andkitreceptors,potentlyinhibitsangiogenesisandinducesregressionintumorxenografts.CancerRes.2006Sep1;66(17):8715-21.PMID:16951187.
